Skip to main content
SpringerLink
Log in

Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States

  • Research Papers
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

This study examines the relationship between fatal breast cancer and use of estrogen replacement therapy (ERT) among women in a large prospective study in the United States. After nine years of follow-up, 1,469 breast cancer deaths were observedin a cohort of 422,373 postmenopausal women who were cancer free at study entry and who supplied information on estrogen use. Results from Cox proportional hazards modeling, adjusted for 11 other potential risk factors, showed that ever-use of ERT was associated with a significantly decreased risk of fatal breast cancer (rate ratio [RR]=0.84,95 percent confidence interval [CI]=0.75–0.94). There was a moderate trend (P=0.07) of decreasing risk with younger age at first use of ERT. This decreased risk was most pronounced in women who experienced natural menopause before the age of 40 years (RR=0.59, CI=0.40–0.87). There was no discernible trend of increasing risk with duration of use in estrogen users at baseline or former users, nor was there any trend in years since last use in former users. The relationship between ERT and breast cancer mortality differed by age at menarche and by a self-reported history of breast cysts. No increased risk of fatal breast cancer with ERT was observed with estrogen use status (baseline/former), age at first use, duration of use, or years since last use. These findings suggest that ever-use of ERT is associated with a 16 percent decreased risk of fatal breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med 1992; 117: 1016–37.

    Google Scholar 

  2. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990; 97: 1080–6.

    Google Scholar 

  3. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75–8.

    Google Scholar 

  4. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. JNCI 1995; 87: 517–23.

    Google Scholar 

  5. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large bowel cancer. JNCI 1995; 87: 1067–71.

    Google Scholar 

  6. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 140: 256–61.

    Google Scholar 

  7. Voight LF, Weiss NS, Chu J, Daling JR, McKnight B, vanBelle G. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–7.

    Google Scholar 

  8. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States 1982–1992. Obstet Gynecol 1995; 85: 6–10.

    Google Scholar 

  9. Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer. Cancer Sup 1994; 74: 1111–24.

    Google Scholar 

  10. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993; 15: 66–79.

    Google Scholar 

  11. Henrich JB. The postmenopausal estrogen/breast cancer controversy. JAMA 1992; 268: 1900–2.

    Google Scholar 

  12. Mills PK, Beeson LW, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in Seventh-Day Adventists. Cancer 1989; 64: 591–7.

    Google Scholar 

  13. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93.

    Google Scholar 

  14. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137–42.

    Google Scholar 

  15. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993; 168: 1473–80.

    Google Scholar 

  16. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994; 5: 415–21.

    Google Scholar 

  17. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994; 5: 491–500.

    Google Scholar 

  18. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogenprogestin replacement. N Engl J Med 1989; 321: 293–7.

    Google Scholar 

  19. Hoover RN, Gray LA, Cole P, MacMahon B. Menopausal estrogens and breast cancer. N Engl J Med 1976; 295: 401–5.

    Google Scholar 

  20. Kaufman DW, Palmer JR, deMouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991; 134: 1375–85.

    Google Scholar 

  21. Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekens CH. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992; 3: 423–9.

    Google Scholar 

  22. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology 1995; 6: 227–30.

    Google Scholar 

  23. Strickland DM, Gambrell RD, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80: 400–4.

    Google Scholar 

  24. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II participants. Am J Epidemiol 1993; 137: 235–41.

    Google Scholar 

  25. World Health Organization. International Classification of Diseases, Ninth Revision. Geneva, Switzerland: WHO, 1977.

    Google Scholar 

  26. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187–220.

    Google Scholar 

  27. Leon DA. A prospective study of the independent effects of parity and age at first birth on breast cancer incidence in England and Wales. Int J Cancer 1989; 43: 986–91.

    Google Scholar 

  28. Kelsey JL, Gammon MD. Epidemiology of breast cancer. Epidemiol Rev 1990; 12: 228–40.

    Google Scholar 

  29. Kleinbaum DG, Kupper LL, Morgenstern H, Epidemiologic Research: Principles and Quantitative Methods. New York, NY (USA): Van Nostrand Reinhold Co. 1982.

    Google Scholar 

  30. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1983; 56: 690–700.

    Google Scholar 

  31. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956; 9: 927–9.

    Google Scholar 

  32. Trichopoulos D, MacMahon B, Cole P. The menopause and breast cancer risk. JNCI 1972; 48: 605–13.

    Google Scholar 

  33. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15: 48–65.

    Google Scholar 

  34. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomark Prev 1995; 4: 319–26.

    Google Scholar 

  35. Bergkvist L, Adami HO, Persson I, Bergstrom R, Kruseno UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 130: 221–8.

    Google Scholar 

  36. Yuen I, Persson I, Bergkvist L, Hoover R, Schairer C, Adami HO. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for ‘healthy drug-user’ effect. Cancer Causes Control 1993; 4: 369–74.

    Google Scholar 

  37. Matthews KA, Bromberger J, Egeland G. Behavioral antecedents and consequences of the menopause. In: Korenman SG, ed. The Menopause: Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Nada, CA (USA): Serono Symposia 1989; 1–10.

  38. Brinton LA, Hoover R, Fraumeni JFJr. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986; 54: 825–32.

    Google Scholar 

  39. Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND. Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 1994; 178: 167–70.

    Google Scholar 

  40. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Peana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995; 85: 11–7.

    Google Scholar 

  41. Schwartzbaum JA, Hulka BS, Fowler WC, Kaufman DG, Hoberman D. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol 1987; 126: 851–60.

    Google Scholar 

  42. Nyholm HCJ, Nielsen AL, Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics. Oncology 1993; 49: 229–35.

    Google Scholar 

  43. Ewertz M, Gillanders S, Meyer L, Zedela K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer 1991; 49: 526–30.

    Google Scholar 

  44. US Department Health and Human Services. National Health Survey. Washington DC: National Center for Health Statistics, 1990; Series 10 (181: Table 58).

    Google Scholar 

  45. Gorsky RD, Koplan JP, Peterson HB, Thaeker SB. Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol 1994; 83: 161–6.

    Google Scholar 

  46. Healy B. Women's health, public welfare. JAMA 1991; 266: 566–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Department of the American Cancer Society, USA

    Dawn B. Willis, Eugenia E. Calle, Heidi L. Miracle-McMahill & Clark W. Heath Jr.

Authors
  1. Dawn B. Willis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugenia E. Calle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heidi L. Miracle-McMahill
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Clark W. Heath Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Willis, D.B., Calle, E.E., Miracle-McMahill, H.L. et al. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7, 449–457 (1996). https://doi.org/10.1007/BF00052671

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00052671

Key words

Search

Navigation